Financial Summary
Consolidated Financial Results for the Three Months ended June 30, 2024 (FY2024)
(Japanese standard)

July 30, 2024

Listed company name: JCR Pharmaceuticals Co., Ltd.
Listed stock exchange: Tokyo Stock Exchange
Code number: 4552 URL: https://www.jcrpharm.co.jp/
Representative: (Title) Representative Director, Chairman and President
(Name) Shin Ashida
Person in charge of inquires: (Title) Senior Corporate Officer, Executive Director, Corporate Strategy Division
(Name) Yoh Ito TEL: 0797(32)1995
Scheduled date to commence dividend payments: -
Preparation of supplemental information for this financial summary: Available
IR Conference: Available

(Fractions smaller than one million yen omitted)

1. Consolidated Financial Results for 1Q FY2024 (April 1, 2024 to June 30, 2024)

(1) Consolidated Operating Results (Cumulative)

(Percentage shows year-on-year changes.)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent	
Three Months Ended	million yen	%	million yen	%	million yen	%	million yen	%
June 30, 2024	8,145	(24.6)	(296)	-	(257)	-	201	(87.5)
June 30, 2023	10,808	12.5	2,066	34.5	2,260	8.5	1,610	17.7

(Reference) Comprehensive income: Three months ended June 30, 2024: 441 million yen ([75.4]%)
Three months ended June 30, 2023: 1,789 million yen (30.5%)

	Ernings per Share (basic)	Erningsper Share (diluted)
Three Months Ended	yen	yen
June 30, 2024	1.61	1.61
June 30, 2023	12.91	12.85

(2) Consolidated Financial Conditions

	Total assets	Net assets	Equity ratio
As of	million yen	million yen	%
June 30, 2024	104,165	55,674	52.4
March 31, 2024	102,226	56,475	54.2

(Reference) Shareholders' equity: As of Jun. 30, 2024: 54,542 million yen
As of Mar. 31, 2024: 55,365 million yen

2. Dividends

	Dividend per share				
	1st quarter	2nd quarter	3rd quarter	Year-end	Annual
	yen	yen	yen	yen	yen
FY2023	—	10.00	—	10.00	20.00
FY2024	—				
FY2024 (Forecast)		10.00	—	10.00	20.00

(Notes) No revisions were made to the most recently announced dividend forecast.

3. Consolidated Forecasts for the Fiscal Year Ending March 31, 2025 (April 1, 2024 to March 31, 2025)

(Percentage figures for the fiscal year represent the changes from the previous year.)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of the parent		Earnings per share
	million yen	%	million yen	%	million yen	%	million yen	%	yen
Year ending March 31, 2025	41,300	(3.7)	5,400	(28.3)	4,600	(36.7)	3,700	(32.8)	29.65

(Notes) No revisions were made to the most recently announced financial results forecast.

*Note

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in consolidation scope): None

(2) Application of specific accounting practices for preparing quarterly consolidated financial statements: None

(3) Changes in accounting policy, changes in accounting estimates and restatements

1. Changes in accounting policy due to the revision of accounting standards, etc. : Yes
2. Changes in accounting policy other than 1. : None
3. Changes in accounting estimates : None
4. Restatements : None

(Note) For details, please refer to "2. Quarterly consolidated financial statements and important notes (3) Notes to quarterly consolidated financial statements (Notes to Changes in Accounting Policies)" on page 9 of the attached materials.

(4) Number of shares outstanding (common stocks)

1.Number of outstanding shares as of the end of the period (including treasury stock)	As of June 30, 2024	129,686,308 shares	As of March 31, 2024	129,686,308 shares
2.Number of treasury stock as of the end of the period	As of June 30, 2024	4,861,414 shares	As of March 31, 2024	4,881,914 shares
3.Average number of shares during the period (quarterly cumulative amount)	As of June 30, 2024	124,813,769 shares	As of June 30, 2023	124,782,090 shares

* Review of accompanying quarterly consolidated financial statements by certified public accountants or auditing firms: None

* Explanation on the appropriate use of forecasts of financial results and other comments

(Note on forward-looking statements, etc.)

Forward-looking statements, such as forecasts of financial results, contained in this document are based on information currently available to the Company and certain assumption that are judged as rational. The Company does not assure the achievement of these forecasts. In addition, actual financial results may differ significantly from forecasts due to various reasons. For assumptions underlying forecasts of financial results and notes regarding the appropriate use of forecasts of financial results, please refer to "1. Qualitative information for quarterly financial statements, (3) Explanation on projections such as forecasts of consolidated financial results" on page 4 of the attached material.

(Millions of yen)

	As of March 31, 2024	As of June 30, 2024
Assets		
Current assets		
Cash and deposits	18,756	18,337
Accounts receivable - trade, and contract assets	14,934	14,056
Merchandise and finished goods	2,111	2,404
Work in process	6,220	6,908
Raw materials and supplies	12,602	12,960
Other	2,955	3,161
Total current assets	57,581	57,828
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	14,140	13,907
Land	10,587	10,587
Construction in progress	171	2,335
Other, net	5,141	4,899
Total property, plant and equipment	30,040	31,730
Intangible assets		
Patent right	2,158	2,088
Other	1,338	1,281
Total intangible assets	3,496	3,370
Investments and other assets		
Investment securities	9,120	9,092
Other	1,991	2,148
Allowance for doubtful accounts	△4	△4
Total investments and other assets	11,107	11,237
Total non-current assets	44,644	46,337
Total assets	102,226	104,165
Liabilities		
Current liabilities		
Accounts payable - trade	890	857
Short-term borrowings	8,950	13,870
Income taxes payable	1,657	216
Special suspense account for tax purpose reduction entry	11,996	11,996
Provision for bonuses	1,016	1,596
Provision for bonuses for directors (and other officers)	114	146
Other	5,510	4,189
Total current liabilities	30,135	32,874
Non-current liabilities		
Long-term borrowings	14,350	14,350
Provision for employee stock ownership plan	81	100
Retirement benefit liability	903	918
Other	280	248
Total non-current liabilities	15,615	15,617
Total liabilities	45,750	48,491

(Millions of yen)

	As of March 31, 2024	As of June 30, 2024
Net assets		
Shareholders' equity		
Share capital	9,061	9,061
Capital surplus	10,384	10,384
Retained earnings	37,278	36,227
Treasury shares	△2,963	△2,952
Total shareholders' equity	53,761	52,721
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	741	732
Deferred gains or losses on hedges	△0	－
Foreign currency translation adjustment	731	962
Remeasurements of defined benefit plans	132	126
Total accumulated other comprehensive income	1,604	1,821
Share acquisition rights	812	812
Non-controlling interests	297	318
Total net assets	56,475	55,674
Total liabilities and net assets	102,226	104,165

(Millions of yen)

	Three months ended June 30, 2023	Three months ended June 30, 2024
Net sales	10,808	8,145
Cost of sales	3,363	2,073
Gross profit	7,445	6,072
Selling, general and administrative expenses	5,379	6,368
Operating profit (loss)	2,066	△296
Non-operating income		
Interest income	0	27
Dividend income	13	17
Foreign exchange gains	484	435
Other	21	24
Total non-operating income	520	505
Non-operating expenses		
Share of loss of entities accounted for using equity method	297	200
Interest expenses	19	26
Commission expenses	2	17
Depreciation	—	214
Other	6	6
Total non-operating expenses	326	466
Ordinary profit (loss)	2,260	△257
Extraordinary income		
Gain on cancellation of contract	—	627
Total extraordinary income	—	627
Extraordinary losses		
Loss on disposal of non-current assets	0	0
Total extraordinary losses	0	0
Profit before income taxes	2,260	369
Income taxes - current	1,122	230
Income taxes - deferred	△469	△65
Total income taxes	653	164
Profit	1,607	204
Profit (loss) attributable to non-controlling interests	△2	3
Profit attributable to owners of parent	1,610	201

(Millions of yen)

	Three months ended June 30, 2023	Three months ended June 30, 2024
Profit	1,607	204
Other comprehensive income		
Valuation difference on available-for-sale securities	68	△9
Deferred gains or losses on hedges	—	0
Foreign currency translation adjustment	35	98
Remeasurements of defined benefit plans, net of tax	2	△6
Share of other comprehensive income of entities accounted for using equity method	75	151
Total other comprehensive income	181	236
Comprehensive income	1,789	441
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	1,789	418
Comprehensive income attributable to non-controlling interests	△0	22